FDA responds to estradiol patch access problems as demand rises

Clinical takeaway: If a patient cannot obtain their usual estradiol patch, coordinate with the pharmacist to identify a substitutable FDA-approved patch when appropriate. If access remains limited, discuss another estradiol option and advise the patient not to stop or change treatment without guidance.

Patients are reporting difficulty obtaining their usual estradiol transdermal patches as growing interest in menopause treatment strains supplies. FDA emphasized that patches remain available, although access to specific products or brands may vary by pharmacy and location.

Supply of FDA-approved estradiol patches has nearly doubled over the past year, but demand has continued to rise. FDA is working with all six manufacturers and may expedite reviews of manufacturing changes intended to increase supply.

FDA attributed the increased demand in part to greater interest in treating menopause symptoms following its November 2025 request for manufacturers to remove boxed-warning language about probable risks of breast cancer, cardiovascular disease, and dementia from menopausal hormone therapy labeling.

Manufacturers are adding production shifts, increasing batch sizes, expanding capacity, and investing in specialized equipment and manufacturing lines. Some measures may improve availability relatively quickly, while larger expansions will take longer because transdermal patches require specialized manufacturing processes. FDA said it will continue monitoring availability as manufacturers work to increase supply.

Source: US Food and Drug Administration. (2026 Sep 3). FDA update on estradiol transdermal patch availability